LifePlus Announces World’s First Non-Invasive Continous Blood Glucose Monitoring Wearable
LifePlus is backed by Silicon Valley-based JLA Advisors with industry visionary, serial tech-entrepreneur and White House Innovation Fellow John Trobough serving as the Executive Chairman of the Board. The announcement was made today at the Medical Wearables Conference in Santa Clara, Calif., where Trobough will also be presenting more LifePlus details to conference attendees tomorrow, May 17 at 2:15 p.m. at the Biltmore Hotel.
“We have been in stealth mode and today we are thrilled to announce the introduction of LifeLeaf as part of the burgeoning medical wearables category,” said Trobough. “Managing diabetes and other chronic diseases requires early and timely detection, rapid intervention and high compliance. LifeLeaf exceeds those requirements with its patent-pending open standards-based software stack and cloud-based analytics. LifeLeaf is different from any other product and software technology available – it is truly unique and we are excited to make this multi-sensor capability available to companies and developers globally.”
LifeLeaf by LifePlus is a multi-sensor wearable smartwatch that continuously and non-invasively monitors and tracks major chronic health risks such as diabetes, cardiac arrhythmia, congestive heart failure, COPD, sleep apnea and hypertension. It is a cloud-based AI solution with a user-interface that is simple and easy to use, as well as a connected mobile app that provides cloud-based analytics with real-time notifications. The product is targeted at the multi-billion-dollar medical wearables market, with an emphasis on the self-monitoring blood glucose market. The LifeLeaf wearable will be available later this year.
LifePlus is about helping people live a better life, whether you’re in great health, staying ahead of future health risks or currently managing a chronic disease. LifeLeaf is a non-invasive medical wearable solution that revolutionizes care for billions of people at risk of living with chronic diseases.
Erin Murphy for LifePlus
Source: JLA Advisors